TaiRx, Inc. and BioHealth Innovation, Inc. announced the formation of TaiRx US, a new joint venture. The mission of the new company is to develop therapeutics and precision medicine diagnostics focused on the Nodal protein, a critical mediator of aggressive cancer progression and treatment resistance. TaiRx, Inc. and BHI have formed TaiRx US, which will be based in Rockville (Montgomery County), Maryland, to develop and commercialize a unique monoclonal antibody with the potential to reverse drug resistance in various tumor types. The company is also working to develop a companion diagnostic to accurately identify those patients who can best benefit from the therapy. The antibody under development targets Nodal, a secreted protein found in aggressive tumors and responsible for rapid growth, metastasis and drug resistance. There are no current therapies that inhibit this critical pathway in cancer. Experimental models demonstrate the promise of reversing cancer progression by targeting Nodal.